Autoantibodies against IFNα in patients with systemic lupus erythematosus and susceptibility for infection: a retrospective case-control study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 07 2022
04 07 2022
Historique:
received:
25
03
2022
accepted:
24
06
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
7
7
2022
Statut:
epublish
Résumé
IFNα and anti-IFNα autoantibodies have been implicated in susceptibility both for systemic lupus erythematosus (SLE) and viral infection. We aimed to analyze the SLE disease phenotype and risk for infection associated with anti-IFN-α IgG autoantibodies in SLE patients In this multidisciplinary retrospective single referral center study, all consecutive patients with SLE admitted between January 1st and November 30th 2020 were considered. All subjects fulfilled the ACR/EULAR 2019 criteria for SLE. Anti-IFNα IgG autoantibodies were quantified at admission by ELISA. Demographic, medical history, laboratory, treatment, and outcome data were extracted from electronic medical records using a standardized data collection form. 180 patients [female 87.2%, median age of 44.4 (34-54.2) years] were included. The median disease duration was 10 years [4-20] with a median SLEDAI score of 2 [0-4] at study time. Fifty-four (30%) patients had a past-history of lupus nephritis. One hundred and forty-four (80%) had received long-term glucocorticoids and 99 (55%) immunosuppressive drugs. Overall, 127 infections-mostly bacterial and viral-were reported in 95 (52.8%) patients. Twenty SLE patients (11.1%) had positive anti-IFNα IgG autoantibodies with a titer ranging from 10 to 103 UA/mL. Age, sex, SLE phenotype and treatment did not significantly differ between SLE patients with or without anti-IFNα. Infection rate was similar in both groups except for tuberculosis which was more frequent in patients with anti-IFNα (20% vs. 3.1%, p = 0.01). The prevalence of autoantibodies against IFNα is high in SLE and associated with a higher frequency of tuberculosis.
Identifiants
pubmed: 35788140
doi: 10.1038/s41598-022-15508-9
pii: 10.1038/s41598-022-15508-9
pmc: PMC9253327
doi:
Substances chimiques
Autoantibodies
0
Immunoglobulin G
0
Interferon-alpha
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11244Informations de copyright
© 2022. The Author(s).
Références
J Interferon Cytokine Res. 2003 Mar;23(3):143-7
pubmed: 12716486
Arthritis Rheumatol. 2016 Jul;68(7):1677-87
pubmed: 26815287
J Immunol. 2014 Jun 15;192(12):5459-68
pubmed: 24907379
Ann Rheum Dis. 2022 Apr;81(4):569-574
pubmed: 34893471
Immunol Rev. 2015 Mar;264(1):103-20
pubmed: 25703555
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
Clin Exp Rheumatol. 2022 Jul;40(7):1450
pubmed: 35238761
Ann Rheum Dis. 2021 Aug;80(8):1101-1102
pubmed: 33727216
Arthritis Rheum. 2011 Aug;63(8):2407-15
pubmed: 21506093
N Engl J Med. 2020 Jan 16;382(3):211-221
pubmed: 31851795
Sci Transl Med. 2013 Jul 10;5(193):193ra89
pubmed: 23843450
Arthritis Rheumatol. 2019 Sep;71(9):1400-1412
pubmed: 31385462
Immunity. 2003 Aug;19(2):225-34
pubmed: 12932356
N Engl J Med. 2003 Oct 16;349(16):1526-33
pubmed: 14561795
Rheumatology (Oxford). 2021 Jan 5;60(1):60-72
pubmed: 33099651
Lancet. 2019 Apr 20;393(10181):1642-1656
pubmed: 30904262
Arthritis Rheum. 2006 Sep;54(9):2951-62
pubmed: 16947629
Arthritis Res Ther. 2012 Jun 27;14(3):R155
pubmed: 22734582
medRxiv. 2020 Dec 29;:
pubmed: 33398302